Related Experiment Video
Updated: Jul 10, 2026
11:16
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
Published on: February 15, 2019
Simian virus 40 vectors for pulmonary gene therapy
Luminita Eid1, Zohar Bromberg, Mahmoud Abd El-Latif
1Department of Anesthesiology and Critical Care Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, 91120, Israel. luminita25@yahoo.com
Respiratory Research
|October 31, 2007
Summary
Simian virus 40 (SV40) vectors efficiently deliver genes to lung cells in a sepsis-induced Acute Respiratory Distress Syndrome (ARDS) model. This study shows SV40 vector feasibility for pulmonary gene therapy in sepsis.
Area of Science:
- Pulmonary gene therapy
- Sepsis research
- Viral vector technology
Background:
- Sepsis is a leading cause of death in critically ill patients.
- Sepsis frequently causes lung damage, leading to Acute Respiratory Distress Syndrome (ARDS).
- Gene transfer is a potential therapeutic strategy for sepsis-induced organ damage.
Purpose of the Study:
- To investigate the feasibility of using simian virus 40 (SV40) vectors for pulmonary gene therapy.
- To assess SV40 vector efficacy in a sepsis-induced ARDS model.
Main Methods:
- Sepsis-induced ARDS was modeled using cecal ligation double puncture (2CLP) in rats.
- SV40 vectors carrying a luciferase reporter gene were administered intratracheally.
- Gene expression, vector distribution, and immune response were evaluated.
Main Results:
- SV40 vectors demonstrated efficient gene expression in the lungs of septic rats.
- Vector presence was confirmed in type II alveolar cells.
- The SV40 vector did not elicit a significant cellular immune response.
Conclusions:
- SV40 vectors show efficient uptake and expression in the lungs during sepsis-induced ARDS.
- These vectors can transduce alveolar type II cells in vivo.
- SV40 vectors represent a potential future therapeutic tool for pulmonary complications of sepsis.
